• 0.4% Trypan Blue Solution: Protocols and Workflow Guidance

  2026-07-14

  0.4% Trypan Blue Solution provides a practical means for researchers to distinguish viable from non-viable cells in cell culture, cytotoxicity, and cell counting workflows. This reagent is essential where direct, dye exclusion-based cell viability measurement is required, but should not be used for diagnostic or clinical applications.

• Saracatinib (AZD0530): Optimizing Src/Abl Kinase Inhibition

  2026-07-13

  Saracatinib (AZD0530) empowers researchers to dissect Src/Abl-driven cancer signaling and synaptic pathways with nanomolar precision. This guide translates recent mechanistic advances into actionable workflows, troubleshooting, and comparative insight for cell-based and in vivo models.

• Optimizing Cancer Research with JNJ-26854165 (Serdemetan)

  2026-07-13

  JNJ-26854165 (Serdemetan) is a next-generation HDM2 antagonist that unlocks precise modulation of the p53 pathway for advanced cancer research. This guide delivers practical protocols, troubleshooting strategies, and evidence-driven insights for maximizing reproducibility and impact in cell proliferation, apoptosis, and radiosensitization workflows.

• Recombinant Annexin V: Advancing Apoptosis Detection in Cell

  2026-07-12

  Brumatti et al. present a robust bacterial expression and purification workflow for recombinant annexin V, enabling sensitive detection of apoptotic membrane changes. This methodological advance streamlines the identification of early apoptosis in mammalian cells, with broad implications for studies of cell death, membrane biology, and disease mechanisms.

• Structural Insights into TRPM3 Modulation by Neurosteroids a

  2026-07-10

  This study provides high-resolution cryo-EM structures revealing how neurosteroids, synthetic agonists, and the anticonvulsant primidone interact with the TRPM3 ion channel. These findings clarify the molecular mechanisms of TRPM3 gating and inhibition, with implications for pain and neurodevelopmental disorder therapeutics.

• Cycloheximide (SKU A8244): Reliable Protein Synthesis Inhibi

  2026-07-09

  This article delivers a scenario-driven, evidence-based guide to applying Cycloheximide (SKU A8244) for robust protein biosynthesis inhibition in cell viability and apoptosis research. Drawing on validated literature and recent mechanistic advances, it addresses practical challenges in experimental design, protocol optimization, and vendor selection. Researchers will find actionable insights to enhance reproducibility and interpretability in workflows using Cycloheximide.

• CBD Modulates Orofacial Inflammatory Pain via Endocannabinoi

  2026-07-09

  This study demonstrates that cannabidiol (CBD) robustly attenuates both sensory and affective dimensions of orofacial inflammatory pain in murine models by targeting endocannabinoid and serotonergic signaling. The findings highlight CBD’s multi-level mechanisms and suggest its translational potential for comprehensive pain management strategies.

• IL-18 Tetrapeptide Tools Reveal Overlapping Caspase Specific

  2026-07-08

  This study introduces a novel IL-18 tetrapeptide-based inhibitor to dissect the substrate and inhibitor specificities of inflammatory and apoptotic initiator caspases. The findings demonstrate unexpected overlap between caspase-1 and caspase-8, clarifying inhibitor selectivity and informing the design of future research tools for cell death and inflammation pathways.

• Pomalidomide (CC-4047): Molecular Profiling and Model Optimi

  2026-07-08

  Explore the advanced application of Pomalidomide (CC-4047) in multiple myeloma research, focusing on molecular model optimization and the integration of mutational landscape insights. This in-depth analysis reveals how refined cellular models and precise immunomodulation can transform experimental outcomes.

• Mechanical Activation of GABAB Receptors: Integrin-Mediated

  2026-07-07

  This study reveals that GABAB receptors, traditionally activated by GABA, can also be directly triggered by mechanical forces such as shear stress through integrin binding, establishing a new paradigm for GPCR activation. The findings highlight a mechanotransduction complex critical for astrocyte remodeling, with broad implications for understanding cell signaling and disease.

• Reliable Protein Detection with ECL Chemiluminescent Substra

  2026-07-07

  This article addresses persistent challenges in protein immunodetection workflows by examining five real-world laboratory scenarios. Drawing on evidence and best practices, it demonstrates how the ECL Chemiluminescent Substrate Detection Kit (Enhanced) (SKU K1230) enables sensitive, reproducible western blot chemiluminescence detection, supporting robust quantitative results in biomedical research.

• SP2509: Lysine-Specific Demethylase 1 Antagonist for AML Res

  2026-07-06

  SP2509 is a highly selective Lysine-specific demethylase 1 antagonist that transforms acute myeloid leukemia (AML) research through targeted epigenetic modulation. Its robust workflow compatibility, clear mechanism, and synergy in apoptosis induction and differentiation make it a pivotal tool for exploring cancer epigenetics and optimizing experimental design.

• PR-619: Broad-Spectrum Deubiquitylating Enzymes Inhibitor Do

  2026-07-06

  PR-619 is a reversible deubiquitylating enzymes inhibitor with broad cellular activity, enabling ubiquitination pathway research without direct proteasome inhibition. Its unique solubility and cytotoxicity profile make it a key tool for cancer and neurodegenerative disease models. APExBIO supplies PR-619 under SKU A8212.

• Perphenazine: Dopamine D2 Receptor Antagonist in Advanced Re

  2026-07-05

  Perphenazine is redefining experimental neuropharmacology and host-pathogen research through its multi-receptor antagonism and robust induction of mitochondria-mediated cell death. Its role in enhancing macrophage antibacterial activity and suppressing opioid tolerance sets it apart for cutting-edge laboratory workflows.

• Antidepressant Effects of Rotigotine in Preclinical Depressi

  2026-07-04

  This study systematically evaluated rotigotine, a non-ergoline dopamine D2/D3 receptor agonist, for antidepressant activity across established rodent models. The findings suggest that rotigotine exerts dose-dependent antidepressant-like effects, expanding its potential beyond motor symptom management in Parkinson’s disease and providing a foundation for further translational research.

444 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page